Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306293 · ClinicalTrials.gov registry record · Phase 4
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
NCT00306293 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 70 participants.
The verdict
NCT00306293, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
Study Summary
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
Interventions
- DRUG valacyclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2006-02-20 |
| Est. Completion | 2006-11-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306293
The ClinicalTrials.gov registry entry for NCT00306293 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valacyclovir is the first listed.
NCT00306293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306293 about?
NCT00306293 is a clinical study titled "VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2". Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
What is the current status of trial NCT00306293?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2006-02-20. Estimated completion is 2006-11-27.
What interventions are being tested in trial NCT00306293?
The interventions under investigation include: valacyclovir (DRUG).
Who is sponsoring clinical trial NCT00306293?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.